Daniel is investigating combinatorial approaches to activate the adaptive immune system and eradicate cancers by targeting co-stimulatory molecules of the TNFR family. He is also interested in the mechanisms underlying OX40- and GITR-driven anti-tumor immunity. In addition, Daniel is engineering chimeric antigen receptor (CAR) T cells for advanced melanomas and characterizing immunotherapy-activated tumor-killing neutrophils.